Andrew Zelenetz, MD, PhD from the Memorial Sloan-Kettering Cancer Center, New York, NY discusses common side-effects observed in the Phase III clinical trial of idelalisib plus bendamustine and rituximab in rlapsed/refractory chronic lymphocytic leukemia (CLL). Idelalisib is associated with colitis, pneumonitis, elevated transaminases, increased risk of febrile neutropenia, but these did not affect overall survival (OS).
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando. FL.